BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 951 filers reported holding BAXTER INTL INC in Q2 2014. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $322,451 | -17.9% | 8,544 | -0.9% | 0.06% | -17.1% |
| Q2 2023 | $392,682 | -12.2% | 8,619 | -21.9% | 0.08% | -7.3% |
| Q1 2023 | $447,458 | -23.1% | 11,032 | -3.3% | 0.08% | -23.4% |
| Q4 2022 | $581,568 | -19.2% | 11,410 | -14.6% | 0.11% | -31.0% |
| Q3 2022 | $720,000 | -8.3% | 13,359 | +9.3% | 0.16% | -3.1% |
| Q2 2022 | $785,000 | -14.7% | 12,219 | +3.0% | 0.16% | +1.3% |
| Q1 2022 | $920,000 | -10.5% | 11,863 | -0.9% | 0.16% | -4.8% |
| Q4 2021 | $1,028,000 | +15.8% | 11,973 | +8.4% | 0.17% | -2.4% |
| Q3 2021 | $888,000 | +194.0% | 11,041 | +150.1% | 0.17% | +38.2% |
| Q1 2015 | $302,000 | -47.0% | 4,414 | -43.2% | 0.12% | -53.6% |
| Q4 2014 | $570,000 | -18.5% | 7,773 | -19.6% | 0.26% | -27.4% |
| Q3 2014 | $699,000 | -23.8% | 9,670 | -23.2% | 0.36% | -21.5% |
| Q2 2014 | $917,000 | -24.5% | 12,585 | -23.8% | 0.46% | -27.7% |
| Q1 2014 | $1,215,000 | -5.7% | 16,515 | -10.9% | 0.64% | -15.1% |
| Q4 2013 | $1,289,000 | -4.6% | 18,532 | -9.9% | 0.76% | -5.7% |
| Q3 2013 | $1,351,000 | -6.7% | 20,573 | -1.6% | 0.80% | -8.3% |
| Q2 2013 | $1,448,000 | – | 20,902 | – | 0.88% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |